CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Summit Therapeutics PLC Company Snapshot
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Sales Analysis.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Summit Therapeutics PLC
  Stock Performance Chart for Summit Therapeutics PLC
 
  Stock Data: Recent Stock Performance:
  Current Price (5/19/2017): 177.50p
(Figures in Pounds Sterling)
1 Week 0.0%   13 Weeks 0.0%  
4 Weeks -6.6%   52 Weeks 59.9%  
 
Summit Therapeutics PLC Key Data:
  Ticker: SUMM Country: United Kingdom
  Exchanges: LON Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2017 Sales 2,304,000
(Year Ending Jan 2018).
Employees: 44
  Currency: Pounds Sterling Market Cap: 109,887,114
  Fiscal Yr Ends: January Shares Outstanding: 61,908,233
  Share Type: Ordinary Closely Held Shares: 7,582,433
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.